【摘要】 目的:观察钙离子拮抗剂(CCB)氨氯地平与血管紧张素II受体拮抗剂(ARB)替米沙坦联合治疗对腹型肥胖高血压患者的降压疗效。方法:92例腹型肥胖[腹围(AC)>85cm(男性)/80cm(女性)]高血压患者被分为单纯腹型肥胖组(A组,体重指数<25kg/m2,n=42)或腹型肥胖超重组(B组,体重指数≥25kg/m2,n=50),观察3个月,比较两组的降压疗效。结果:(1)两组血压达标率随着随访时间增加而增加,但无显著差异(P>0.05),2周治疗达标率A组为69.1%,B组为76.0%;(2)治疗3个月A组收缩压、脉压下降的幅度明显大于B组(P均<0.05)。结论:氨氯地平与替米沙坦联合治疗能有效控制腹型肥胖高血压者的血压,对降低单纯腹型肥胖高血压患者的收缩压及脉压更有效。更多还原

【Abstract】 Objective:To observe the therapeutic effect of amlodipine combined with telmisartan in patients with hypertension of abdomen obesity.Methods:A total of 92 hypertension patients with abdomen obesity (abdominal circumference (AC)>85cm (male)/80cm(female) were divided into simple abdomen obesity group (group A,BMI<25kg/m2,n=42) and abdomen obesity with overweight group (group B,BMI≥25kg/m2,n=50).All subjects were observed for 6 months.Results:(1)The rate up to the standard BP increased with follow-up time,and of two group(group A 69.1%,group B 76.0% on 2-week after therapy) was no significant(P>0.05);(2)The decrease amplitude of systolic blood pressure (SBP) pulse pressure(PP) of group A was more than that of group B on 3 month follow-up (P<0.05).Conclusion:Amlodipine combined with telmisartan had a good clinical efficacy in hypertensive patients with abdomen obesity,especially for decreasing SBP and pulse pressure in hypertension patients with abdomen obesity.更多还原